SI4070800T1 - Režim kladribina za zdravljenje multiple skleroze - Google Patents

Režim kladribina za zdravljenje multiple skleroze

Info

Publication number
SI4070800T1
SI4070800T1 SI200532321T SI200532321T SI4070800T1 SI 4070800 T1 SI4070800 T1 SI 4070800T1 SI 200532321 T SI200532321 T SI 200532321T SI 200532321 T SI200532321 T SI 200532321T SI 4070800 T1 SI4070800 T1 SI 4070800T1
Authority
SI
Slovenia
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
SI200532321T
Other languages
English (en)
Slovenian (sl)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4070800(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono S.A. filed Critical Merck Serono S.A.
Publication of SI4070800T1 publication Critical patent/SI4070800T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200532321T 2004-12-22 2005-12-20 Režim kladribina za zdravljenje multiple skleroze SI4070800T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP22166610.0A EP4070800B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
SI4070800T1 true SI4070800T1 (sl) 2025-03-31

Family

ID=36227798

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200532321T SI4070800T1 (sl) 2004-12-22 2005-12-20 Režim kladribina za zdravljenje multiple skleroze
SI200532191T SI2805723T1 (en) 2004-12-22 2005-12-20 Cladribine regimen for the treatment of multiple sclerosis
SI200532305T SI3332789T1 (sl) 2004-12-22 2005-12-20 Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200532191T SI2805723T1 (en) 2004-12-22 2005-12-20 Cladribine regimen for the treatment of multiple sclerosis
SI200532305T SI3332789T1 (sl) 2004-12-22 2005-12-20 Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze

Country Status (25)

Country Link
US (2) US7713947B2 (https=)
EP (7) EP3332789B1 (https=)
JP (7) JP5795456B2 (https=)
KR (1) KR20070091662A (https=)
AR (1) AR052830A1 (https=)
AU (2) AU2005318190B2 (https=)
BR (1) BRPI0517132B8 (https=)
CA (2) CA3087419C (https=)
CY (3) CY1112614T1 (https=)
DK (3) DK3332789T3 (https=)
EA (1) EA015799B1 (https=)
ES (2) ES3007339T3 (https=)
FI (1) FI4070800T3 (https=)
FR (1) FR18C1008I2 (https=)
HR (1) HRP20120228T1 (https=)
HU (3) HUE059133T2 (https=)
IL (2) IL183930A0 (https=)
LT (3) LT3332789T (https=)
LU (1) LUC00064I2 (https=)
MX (1) MX2007007610A (https=)
NO (1) NO20073813L (https=)
PL (4) PL3332789T3 (https=)
SG (1) SG160391A1 (https=)
SI (3) SI4070800T1 (https=)
WO (1) WO2006067141A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
EP3713582A1 (en) * 2017-11-24 2020-09-30 Merck Patent GmbH Cladribine regimen for use intreating progressive forms of multiple sclerosis
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
ES2182920T3 (es) 1994-12-22 2003-03-16 Ortho Pharma Corp Formulaciones solubles de 2-cloro02'-deoxiadenosina.
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
ES2405825T3 (es) 2002-09-25 2013-06-03 Brigham Young University Método para la preparación de compuestos 2-halo-2'-desoxiadenosina a partir de 2'-desoxiguanosina
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2004216485B2 (en) * 2003-02-25 2009-06-11 Merck Serono Sa Combined use of ribavirin and interferon beta in demyelinating diseases
HRP20050924A2 (en) 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
ES2409884T3 (es) * 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
EP3332789B1 (en) 2004-12-22 2022-04-06 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) * 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
LT3332789T (lt) 2022-07-25
CA3087419C (en) 2023-03-07
LTPA2018503I1 (lt) 2018-03-12
ES2921858T3 (es) 2022-09-01
EP2275110B1 (en) 2013-07-10
EA015799B1 (ru) 2011-12-30
EP4070800A1 (en) 2022-10-12
EP2805723B1 (en) 2018-01-17
EP2263678A2 (en) 2010-12-22
LTC2805723I2 (lt) 2022-04-25
BRPI0517132A (pt) 2008-09-30
FR18C1008I1 (https=) 2018-03-30
IL212421A (en) 2014-01-30
CA3087419A1 (en) 2006-06-29
EP3332789B1 (en) 2022-04-06
SG160391A1 (en) 2010-04-29
BRPI0517132B1 (pt) 2020-02-18
WO2006067141A1 (en) 2006-06-29
LT4070800T (lt) 2025-01-10
PL3332789T3 (pl) 2022-08-22
JP2015180685A (ja) 2015-10-15
JP6290962B2 (ja) 2018-03-07
JP6092945B2 (ja) 2017-03-08
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
JP2020193206A (ja) 2020-12-03
HRP20120228T1 (hr) 2012-04-30
KR20070091662A (ko) 2007-09-11
AR052830A1 (es) 2007-04-04
HUE070333T2 (hu) 2025-05-28
AU2011200768B2 (en) 2012-09-13
IL212421A0 (en) 2011-06-30
SI2805723T1 (en) 2018-02-28
JP5908863B2 (ja) 2016-04-26
US20090081163A1 (en) 2009-03-26
FI4070800T3 (fi) 2025-01-14
PL1827461T3 (pl) 2012-07-31
SI3332789T1 (sl) 2022-08-31
MX2007007610A (es) 2007-08-03
EA200701221A1 (ru) 2008-02-28
ES3007339T3 (en) 2025-03-19
US8377903B2 (en) 2013-02-19
EP3332789A1 (en) 2018-06-13
EP2263678B1 (en) 2014-06-11
CY1112614T1 (el) 2016-02-10
AU2011200768A1 (en) 2011-03-17
JP2013216664A (ja) 2013-10-24
AU2005318190B2 (en) 2010-11-25
EP2805723A1 (en) 2014-11-26
PL2805723T3 (pl) 2018-04-30
EP4523753A2 (en) 2025-03-19
CA2588966A1 (en) 2006-06-29
FR18C1008I2 (fr) 2019-03-01
JP5795456B2 (ja) 2015-10-14
HUS1800009I1 (hu) 2018-05-02
IL183930A0 (en) 2007-10-31
EP4523753A3 (en) 2025-05-28
HUE059133T2 (hu) 2022-10-28
EP2275110A3 (en) 2011-04-27
CY2018006I2 (el) 2018-06-27
JP2008524313A (ja) 2008-07-10
CY2018006I1 (el) 2018-06-27
PL4070800T3 (pl) 2025-03-10
CA2588966C (en) 2020-07-21
JP2017101061A (ja) 2017-06-08
EP1827461A1 (en) 2007-09-05
CY1119790T1 (el) 2018-06-27
AU2005318190A1 (en) 2006-06-29
LUC00064I2 (https=) 2018-03-28
EP2263678A3 (en) 2011-04-27
DK2805723T3 (da) 2018-01-29
US20100203017A1 (en) 2010-08-12
JP2018165271A (ja) 2018-10-25
LUC00064I1 (https=) 2018-02-14
JP6430554B2 (ja) 2018-11-28
JP2016138128A (ja) 2016-08-04
US7713947B2 (en) 2010-05-11
BRPI0517132B8 (pt) 2021-05-25
NO20073813L (no) 2007-09-21
EP4070800B1 (en) 2024-10-16
EP2275110A2 (en) 2011-01-19
EP1827461B1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
HUS1800009I1 (hu) Kladribin adagolási elõírás szklerózis multiplex kezelésére
ZA200808852B (en) Cladribine regimen for treating multiple sclerosis
IL179139A0 (en) Method for treating multiple sclerosis
IL183900A0 (en) Polymerization processes
EP1773679A4 (en) PACKAGING
GB0418046D0 (en) Eantioselective process
ZA200800123B (en) Method for diagnosing multiple sclerosis
ZAA200501234S (en) Packages
GB0421928D0 (en) Process
EP1827491A4 (en) TREATMENT OF MULTIPLE SCLEROSIS
EP1812665A4 (en) MACHINE FOR HEAVY-HEAD EXTRACTION FOR CUTTED SURFACES
IL180446A0 (en) Object process graph application controller-viewer
TWI367216B (en) Process for stopping continuous polymerization
HU0400305D0 (en) Set for spine-fixture
GB0414335D0 (en) Process
PT4070800T (pt) Regime de cladribina para o tratamento de esclerose múltipla
ZA200704868B (en) Cladrlbine regimen for treating multiple sclerosis
GB2411101B (en) Glove
GB0428294D0 (en) Process
GB0413084D0 (en) Process
GB0427968D0 (en) Process
GB0401540D0 (en) Process
GB0614058D0 (en) Treatment for multiple sclerosis
AU157093S (en) Tunic
AU157092S (en) Tunic